Tag: immunotherapy
Search News
Novel insights into graft-versus-host disease
13th October 2020
Research led by Barts Cancer Institute, Queen Mary University of London, has identified a subset of immune cells involved in site-specific tissue damage in cancer patients who have developed harmful graft-versus-host disease after stem cell transplantation. The insights gained from the study may help to define new targets for more selective approaches to prevent or treat this condition in patients who have received a stem cell transplant.
Read more
Immune ‘cloaking’ in cancer cells
14th September 2020
Researchers have created a mathematical model that can determine the impact of the immune system on tumour evolution. The information gained from using this model may be able to be used to predict whether immunotherapy is likely to be effective for a patient’s cancer, helping to guide treatment decisions.
Read more
KEYNOTE-522: Immune therapy for breast cancer
30th September 2019
Results of an interim analysis from the KEYNOTE-522 trial have shown a treatment combination of immunotherapy plus chemotherapy to improve response rates in patients with early triple-negative breast cancer. Prof Peter Schmid presented the results at the ESMO Congress 2019 in Barcelona, Spain.
Read more
CRUK Career Establishment Award
4th July 2019
Dr Oliver Pearce has received a Cancer Research UK Career Establishment Award, which will fund a project that will look at restoring response to immunotherapy in triple-negative breast cancer.
Read more
New phase III clinical trial using combination therapy extends survival in triple-negative breast cancer
22nd October 2018
Research provides new hope for people with an aggressive type of breast cancer.
Read more
Immunotherapy shows promise for patients with metastatic triple-negative breast cancer
17th October 2018
Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC).
Read more